Wikisage, the free encyclopedia of the second generation, is digital heritage
Epilepsy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 43: | Line 43: | ||
|colspan="3" | xr | |colspan="3" | xr | ||
|-style="vertical-align:top; background:#ffffff;" | |-style="vertical-align:top; background:#ffffff;" | ||
|align="left" style="background:#99ff99"|''' | |align="left" style="background:#99ff99"|'''topiramate''' || | ||
|colspan="3" | [[XR-topiramate|xr]] | |colspan="3" | [[XR-topiramate|xr]] | ||
|- | |- | ||
| Line 60: | Line 60: | ||
==Links== | ==Links== | ||
[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2007.01414.x/pdf Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population] | [http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2007.01414.x/pdf Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population] | ||
[[Dravet's syndrome]] | [[Dravet's syndrome]] | ||
[[Category:Disease]] | |||
{{refs}} | {{refs}} | ||
[[nl:epilepsie]] | [[nl:epilepsie]] | ||
Revision as of 21:25, 25 July 2015
Classification of ethiology could divided in four categories:
- idiopathic epilepsy
- symptomatic epilepsy
- provoked epilepsy
- cryptogenic epilepsy
[1] It is difficult to distinguish between genetic and cryptogenic syndromes.
Morbility data is difficult to interpret when WHO[2] states 50 millions persons affect by epilepsy[3]
nonadherence appears to be associated with increased health care costs,nevertheless XR-medicine appears as strategy to overcome compliance wih AED[4]
|
Medicines | ||||
| type | ,,, | ,,,, | ||
| INN | Generic | slow release | ||
| carbamazepine | normal | xr | ||
| lamotrigine | normal | xr | ||
| levetiracetam | normal | xr | ||
| oxcarbazepine | ... | xr | ||
| phenitoin | ... | xr | ||
| valproate | xr | |||
| topiramate | xr | |||
|
AED | ||||
ILAE Classification
[5] [6] [7] A new perspective for Epileptic Disorders
Links
Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population
| References: |